SPRO · Company research
Spero Therapeutics, Inc. (SPRO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight | The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market. | View source ↗ | GlobeNewswire Inc. | Oct 12, 2026 | bullish | 1 | 1 |
| Spero Therapeutics (SPRO) Slips 1.68% to $1.17, Holding Above $1.11 Support - Revenue Weighted - https://www.siam.in/ | Spero Therapeutics (SPRO) Slips 1.68% to $1.17, Holding Above $1.11 Support - Revenue Weighted https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 5, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics (SPRO) Slips 1.68% to $1.17, Holding Above $1.11 Support - Schiff Line - dars.gov.et | Spero Therapeutics (SPRO) Slips 1.68% to $1.17, Holding Above $1.11 Support - Schiff Line dars.gov.et | View source ↗ | dars.gov.et | Oct 5, 2026 | neutral | 0 | 0.6 |
| New Spero hires get stock awards, but vesting starts after a year - Stock Titan | New Spero hires get stock awards, but vesting starts after a year Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics (NasdaqGS:SPRO) Stock Forecast & Analyst Predictions - Simply Wall Street | Spero Therapeutics (NasdaqGS:SPRO) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 14, 2026 | neutral | 0 | 0.6 |
| A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan | A biotech CEO will speak in New York Sept. 15. Spero will stream it. Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) - Yahoo Finance | Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) Yahoo Finance | View source ↗ | Yahoo Finance | Jul 14, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics: 'Buy' Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO) - Seeking Alpha | Spero Therapeutics: 'Buy' Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 14, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice - GuruFocus | Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice GuruFocus | View source ↗ | GuruFocus | Jul 14, 2026 | neutral | 0 | 0.6 |
| Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) - Seeking Alpha | Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 14, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029 | SPRO Stock News - Quiver Quantitative | Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029 | SPRO Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 14, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey | Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution TradingKey | View source ↗ | TradingKey | Jun 29, 2026 | neutral | 0 | 0.6 |
| $SPRO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative | $SPRO stock is up 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 26, 2026 | neutral | 0 | 0.6 |
| SPRO Forecast — Price Target — Prediction for 2027 - TradingView | SPRO Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics stock surges on FDA approval of Utebzi - Investing.com | Spero Therapeutics stock surges on FDA approval of Utebzi Investing.com | View source ↗ | Investing.com | Jun 18, 2026 | neutral | 0 | 0.6 |
| Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) - Yahoo Finance | Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) Yahoo Finance | View source ↗ | Yahoo Finance | Jun 18, 2026 | neutral | 0 | 0.6 |
| SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - www.timothysykes.com | SPRO Stock Slumps As Volatility Grips Small-Cap Biotech www.timothysykes.com | View source ↗ | www.timothysykes.com | Jun 17, 2026 | neutral | 0 | 0.6 |
| $SPRO stock is down 23% today. Here's what we see in our data. - Quiver Quantitative | $SPRO stock is down 23% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 17, 2026 | neutral | 0 | 0.6 |
| Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price: Oct 16 Close $1.10 - Gotrade | Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price: Oct 16 Close $1.10 Gotrade | View source ↗ | Gotrade | May 17, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.